netFormulary NHS
Southampton Joint Formulary
 Search
 Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
10.01.03  Expand sub section  Drugs which suppress the rheumatic disease process
10.01.03  Expand sub section  Gold
10.01.03  Expand sub section  Penicillamine
10.01.03  Expand sub section  Antimalarials
10.01.03  Expand sub section  Drugs affecting the immune response to top
10.01.03  Expand sub section  Cytokine modulators
Abatacept (Orencia)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Link  NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
   
Adalimumab/ adalimumab biosimilar (Humira, Imraldi, Amgevita ) (Rheumatology)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Specify brand

Imraldi and Amgevita are black triangle

 
Link  NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Link  NICE TA199: Psoriatic arthritis
Link  NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
   
ApremilastBlack Triangle
(tab)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA455: Apremilast for active psoriatic arthritis
   
BelimumabBlack Triangle (Benlysta )
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
   
Certolizumab Pegol (Cimzia)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Link  NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Link  NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD
   
Etanercept/etanercept biosimilar (Enbrel, Benepali, Erelzi) (Rheumatology)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

note Specify brand

Erelzi is black triangle

 
Link  NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Link  NICE TA199: Psoriatic arthritis
Link  NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
   
Golimumab (Simponi) (Rheumatology)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA220: Golimumab for the treatment of psoriatic arthritis
Link  NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
   
Infliximab/infliximab biosimilar (rheumatology)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

note Specify brand (e.g. Remicade®, Remsima®, Inflectra®, Flixabi®, Zessly®)

 

 
Link  NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Link  NICE TA199: Psoriatic arthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
   
IxekizumabBlack Triangle (Taltz)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
   
Rituximab/rituximab biosimilar (MabThera, Rixathon, Truxima) (Rheumatology & Other)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

Also for pemphigus vulgaris (MabThera brand only).

unlicensed off label use in pemphigoid; nephrotic syndrome (children); systemic lupus erythematosus in adults/post-pubescent children; anti-NMDAR autoimmune encephalitis (all ages); immunoglobulin G4-related disease.

Not NHS Not routinely commissioned for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), vasculitis of the peripheral nervous system & IgM paraprotein-associated demyelinating neuropathy (adults) or for connective tissue disease associated with interstitial lung disease - see NHS England Commissioning Policies.

note Specify brand

Rixathon and Truxima black triangle

 

 
Link  NHS England Clinical Commissioning Policy: Rituximab for CIDP, MMN, vasculitis of the peripheral nervous system & IgM paraprotein-associated demyelinating neuropathy (adults)
Link  NHS England Clinical Commissioning Policy: Rituximab for connective tissue disease associated with interstitial lung disease
Link  NHS England Clinical Commissioning Policy: Rituximab for immunoglobulin G4-related disease
Link  NHS England Clinical Commissioning Policy: Rituximab for refractory SLE in adults and post-pubescent children
Link  NHS England Clinical Commissioning Policy: Rituximab for second line treatment for anti-NMDAR autoimmune encephalitis (all ages)
Link  NHS England Clinical Commissioning Policy: Rituximab for the treatment of ANCA-associated vasculitis in adults
Link  NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Link  NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
   
Sarilumab (Kevzara)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA485:Sarilumab for moderate to severe rheumatoid arthritis
   
SecukinumabBlack Triangle (Cosentyx) (Rheumatology)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Rheumatology indications

 
Link  NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Link  NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
   
Tocilizumab (RoActemra)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

unlicensed Also used off-label for toxicities associated with CAR-T cell therapy

 

Restricted Item Not for use in Covid-19 treatment outside of clinical trials. Seek further advice from infection control specialist/pharmacy team.

 
Link  NHS England/UK Chief Medical Officers’ joint letter: Novel coronavirus: clinical trials April 2020
Link  NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
Link  NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA518:Tocilizumab for treating giant cell arteritis
   
Tofacitinib (XELJANZ)
(tablets)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Link  NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
   
10.01.03  Expand sub section  Sulfasalazine
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine

Traffic Light Status Information

Status Description

Green

Suitable for prescribing by all in both primary and secondary care.  

Amber Recommended

Specialist recommended but suitable for continuation in primary care.  

Amber Initiation

Specialist initiated but suitable for continuation in primary care.  

Amber SCG

Specialist initiated and for continuation in primary care under a locally approved shared care guideline.  

Red

Suitable for prescribing in specialist settings (secondary care) only.   

Red Specialist Centre

Secondary care medicines to be used under specialised commissioning arrangements only.  

Blue

For primary care, either via FP10 or supplied through specialist services. These products may be stocked by hospital pharmacies only for supply to primary care units/wards or for continuing supplies for patients admitted on therapy.  

Black

Not recommended for use.  

netFormulary